Desogestrel
| |
| Desogestrel
| |
| Systematic (IUPAC) name | |
| 13-ethyl-17-ethynyl- 11-methylidene- 1,2,3,6,7,8,9,10,12,13,14,15, 16,17- tetradecahydrocyclopenta[a] phenanthren-17-ol | |
| Identifiers | |
| CAS number | |
| ATC code | G03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C22H30O |
| Mol. mass | 310.473 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 98.3% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Desogestrel | |
|
Articles | |
|---|---|
|
Most recent articles on Desogestrel Most cited articles on Desogestrel | |
|
Media | |
|
Powerpoint slides on Desogestrel | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Desogestrel at Clinical Trials.gov Clinical Trials on Desogestrel at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Desogestrel
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Desogestrel Discussion groups on Desogestrel Patient Handouts on Desogestrel Directions to Hospitals Treating Desogestrel Risk calculators and risk factors for Desogestrel
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Desogestrel | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Desogestrel is a molecule used in hormonal contraceptives.
Controversy
In February of 2007, the consumer adovcacy group Public Citizen released a petition requesting that the FDA ban oral contraceptives containing desogestrel, citing studies going as far back as 1995 that suggest the risk of dangerous blood clots is doubled for women on such pills in comparison to other oral contraceptives.
Most combined oral contraceptive pills (COCPs, or simply OCs) on the market today contain both an estrogen compound (ethinyl estradiol is common) plus a progestin (a progesterone-like compound) such as desogestrel.
As such, desogestrel-containing birth control pills are sometimes referred to as "third generation" oral contraceptives. Drugs cited specifically in the petition include Apri-28, Cyclessa, Desogen, Kariva, Mircette, Ortho-Cept, Reclipsen, Velivet and some generic pills. Birth control pills that are considered "second generation" (Ortho Tri-Cyclen, for example) contain an estrogen and a progestin, but the progestin is different, such as levonorgestrel.
The dispute is whether third generation OCs are less safe than the second generations OCs, which are considered the current "gold standard" in terms of oral contraceptive safety.
See also
References
- Public Citizen’s Health Research Group: Petition to the U.S. Food and Drug Administration to Ban Third Generation Oral Contraceptives Containing Desogestrel due to Increased Risk of Venous Thrombosis HRG Publication #1799, 2007
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
